Quidel Co. (NASDAQ:QDEL) Director Kenneth F. Buechler sold 4,000 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $68.86, for a total value of $275,440.00. Following the sale, the director now owns 54,433 shares in the company, valued at approximately $3,748,256.38. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
QDEL stock traded down $1.26 during midday trading on Friday, reaching $67.16. The company’s stock had a trading volume of 248,362 shares, compared to its average volume of 216,918. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.83 and a current ratio of 1.40. The stock has a fifty day simple moving average of $60.05 and a two-hundred day simple moving average of $60.72. Quidel Co. has a 1 year low of $44.27 and a 1 year high of $74.78. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of 23.82, a PEG ratio of 1.00 and a beta of 1.39.
Quidel (NASDAQ:QDEL) last released its earnings results on Thursday, August 8th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. Quidel had a return on equity of 23.34% and a net margin of 13.71%. The business had revenue of $108.25 million for the quarter, compared to analyst estimates of $108.40 million. During the same quarter last year, the firm posted $0.36 earnings per share. The business’s revenue was up 4.9% compared to the same quarter last year. As a group, analysts forecast that Quidel Co. will post 2.69 EPS for the current fiscal year.
Several analysts recently weighed in on QDEL shares. Canaccord Genuity restated a “buy” rating and set a $70.00 price target on shares of Quidel in a report on Monday, July 1st. Craig Hallum upgraded Quidel from a “hold” rating to a “buy” rating and increased their target price for the stock from $63.00 to $75.00 in a research note on Thursday, August 29th. TheStreet lowered Quidel from a “b” rating to a “c+” rating in a research note on Thursday, August 8th. ValuEngine upgraded Quidel from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, BidaskClub lowered Quidel from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Quidel currently has a consensus rating of “Buy” and an average target price of $73.00.
Quidel Company Profile
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Further Reading: S&P 500 Index
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.